Table 2.

Comparison of Renal Outcomes and Mortality Rates Between Patients Starting Antiretroviral Therapy With or Without TDF^a

Baseline eGFR Decrease	Difference in eGFR (95% CI), mL/min		Progression to Renal Dysfunction, OR (95% CI)		Mortality, sHR (95% CI)
	At 6 mo	At 12 mo	Severe	Moderate/Severe
None	−8.64 (−9.40 to −7.88)	−9.93 (−10.7 to −9.14)	3.09 (1.85–5.17)	3.11 (2.52–3.87)	1.22 (1.13–1.31)
Mild	−4.55 (−6.42 to −2.68)	−6.81 (−9.01 to −4.61)	5.27 (1.19–23.2)	2.43 (1.80–3.28)	0.82 (.68–.98)
Moderate	−6.10 (−11.0 to −1.23)	−5.37 (−10.9 to .14)	1.11 (.46–2.70)	NA	0.79 (.58–1.07)
Severe	19.3 (2.29–36.20)	21.7 (4.33–39.10)	NA	NA	0.89 (.52–1.52)

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; NA, not applicable; OR, odds ratio; sHR, subhazard ration; TDF, tenofovir disoproxil fumarate.

^a The comparison was done using the chronic kidney disease–epidemiology formula, with patients not receiving TDF serving as the reference group. All analyses are adjusted for age, sex, calendar year, baseline World Health Organization stage, CD4 cell count, and anemia status.